Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 20, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 12,442 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on September 19, 2005, and was advised to the Company on September 20, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
Important Facts for Investors
- Transaction Type: Transfer of shares from the GSK Trust to employee plan participants.
- Share Volume: 12,442 Ordinary Shares were transferred.
- Directors Involved: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop are noted as having an interest in the shares held in the GSK Trust in the same capacity as other employees.
- Financial Data: No financial metrics are disclosed in this specific filing.